Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. There's no chance participants could get infected from the shots, because they don't contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests.
ALSO READ: Coronavirus in numbers: Latest Covid-19 cases and deaths in India and world
Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. Importantly, they're pursuing different types of vaccines shots developed from new technologies that not only are faster to produce than traditional inoculations but might prove more potent.
Some researchers even aim for temporary vaccines, such as shots that might guard people's health a month or two at a time while longer-lasting protection is developed.
For most people, the new coronavirus causes only mild or moderate symptoms, such as fever and cough. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia.
The worldwide outbreak has sickened more than 156,000 people and left more than 5,800 dead. The death toll in the United States is more than 50, while infections neared 3,000 across 49 states and the District of Columbia. The vast majority of people recover.
According to the World Health Organization, people with mild illness recover in about two weeks, while those with more severe illness may take three weeks to six weeks to recover.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.